Short answer
ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on May 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Exclusive U.S. development and supply agreement with Japan BCG Laboratory for Tokyo-172 BCG.
ImmunityBio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive U.S. development and supply agreement with Japan BCG Laboratory for Tokyo-172 BCG
- ImmunityBio bears all preclinical, clinical, and regulatory approval responsibilities
- Ten-year exclusive U.S. commercialization term begins upon FDA approval
- No payments before FDA approval; free regulatory-submission vials reduce near-term cash requirements
- Post-approval minimum purchase commitment of 2 batches annually creates future supply obligations
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ImmunityBio, Inc. 8-K filings
Get the next IBRX 8-K as it lands
Follow IBRX for push alerts, or ask the research agent what this filing means.